ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
80 announcements with these filters
Alembic Pharmaceuticals Limited redeemed Commercial Papers worth ₹150 Crore on their maturity date. This successful repayment demonstrates the company's strong liquidity and financial discipline.
Mr. Goldee Pardesi has resigned as Associate Vice President - Sales & Marketing at Alembic Pharmaceuticals Limited, effective May 5, 2026. He is leaving to pursue new professional challenges and personal goals. The company has formally disclosed this cessation of senior management personnel to the exchanges.
Mr. Goldee Pardesi has resigned as Associate Vice President - Sales & Marketing at Alembic Pharmaceuticals Limited, effective May 5, 2026. He is leaving to pursue new professional challenges and personal goals. The company reported this cessation under the Senior Management Personnel category.
Alembic Pharmaceuticals Limited announced the resignation of Mr. Goldee Pardesi, Associate Vice President – Sales & Marketing. He was relieved from his duties effective close of business hours on May 4, 2026, to pursue other professional opportunities. The departure is part of a standard senior management transition.
Alembic Pharmaceuticals Limited has appointed Mr. Amit Nayak as Vice President - Commercial Excellence, effective May 1, 2026. Mr. Nayak brings 12 years of experience from firms including Cipla and EY. He will lead commercial excellence initiatives through digital enablement and optimized sales operations.
Alembic Pharmaceuticals Limited has appointed Mr. Amit Nayak as Vice President - Commercial Excellence, effective May 1, 2026. Mr. Nayak brings 12 years of experience from firms like Cipla and EY. He will lead commercial excellence through optimized sales operations and digital enablement.
Alembic Pharmaceuticals has designated Mr. Amit Nayak, Vice President - Commercial Excellence, as Senior Management Personnel effective May 1, 2026. Mr. Nayak brings 12 years of experience from firms including J B Chemicals, Cipla, and EY. This designation aligns with SEBI listing regulations regarding senior management disclosures.
Alembic Pharmaceuticals Ltd has scheduled a Board Meeting on May 15, 2026. The board will consider and approve audited financial results for the quarter and year ended March 31, 2026, and recommend a dividend. The trading window remains closed until 48 hours after the results declaration.
Alembic Pharmaceuticals Limited announced the demise of Mr. Saibal Mukherjee, Resident Director (General Manager - Corporate Relations), on April 26, 2026. Mr. Mukherjee was a Senior Management Personnel based at the company's Delhi office.
Alembic Pharmaceuticals Limited announced the sad demise of Mr. Saibal Mukherjee, Resident Director (Delhi Office), on April 26, 2026. Mr. Mukherjee joined the company in 2014 and was an integral part of the senior management team. The company expressed deep condolences to his family for this irreparable loss.
Alembic Pharmaceuticals received USFDA final approval for Fingolimod Capsules, 0.5 mg, used for treating relapsing forms of multiple sclerosis. The product has an estimated annual market size of approximately ₹1363.0 Crore (US$ 145 million). This marks the company's 237th cumulative ANDA approval, strengthening its US generic portfolio.
Alembic Pharmaceuticals Limited has incorporated a new wholly-owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany. The company invested EUR 25,000 (₹0.27 Crore) to establish this entity, which will promote and distribute pharmaceutical products in the region.
Alembic Pharmaceuticals Limited has incorporated a wholly owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany with a share capital of EUR 25,000 (₹0.27 Crore). The new entity will explore business opportunities and promote, sell, and distribute the company's pharmaceutical products in the German market.
Alembic Pharmaceuticals Limited has incorporated a new subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The company invested ₹2.00 Crore (12 million Philippine Pesos) for a 99.99% stake to promote and distribute pharmaceutical products in the region.
Alembic Pharmaceuticals Limited incorporated a new subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The company invested 12 million Philippine Pesos (₹1.85 Crore) for a 99.99% stake to promote and distribute pharmaceutical products in the region. This expansion marks a strategic entry into the Philippines market.
Alembic Pharmaceuticals Limited has incorporated a subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The company holds a 99.99% stake in the new entity, which has a share capital of 12 million Philippine Pesos. The subsidiary will explore business opportunities to promote and distribute pharmaceutical products in the region.
Alembic Pharmaceuticals Limited received USFDA final approval for Methotrexate Injection USP in multi-dose and single-dose vials. The drug is indicated for neoplastic diseases, rheumatoid arthritis, and severe psoriasis. This marks the company's 236th ANDA approval, strengthening its generic injectable portfolio in the US market.
Alembic Pharmaceuticals Limited certified the full utilization of ₹400 Crore raised through Commercial Papers issued between January and March 2026. The funds were deployed for purposes disclosed in the respective documents, ensuring compliance with SEBI listing conditions.
Alembic Pharmaceuticals received USFDA final approval for Dapagliflozin Tablets (5 mg and 10 mg), used for type 2 diabetes and heart failure. The product addresses a US$ 10,487 million (₹9,752.91 Crore) market. As a Paragraph IV applicant, Alembic is eligible for 180 days of shared generic exclusivity, marking its 217th final ANDA approval.
Alembic Pharmaceuticals Ltd submitted an annual compliance certificate from a Chartered Accountant for the CRA Family Trust. The certificate confirms compliance with the SEBI Exemption Order dated September 30, 2020, for the financial year ended March 31, 2026.